Recent Updates
Recently added Catalysts

Vincerx Pharma, Inc.

VINCFDA catalysts, PDUFA dates & pipeline intelligence
$0.01
▲ +0 · +1.18%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full VINC financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.1852W HIGH $187.44
Volume
475.00
Value Traded
6.03
Short % Float
2.94%
Days to Cover
1.0
-61.54%Week
-83.36%1 Month
-96.2%3 Month
-98.63%6 Month
-99.95%5 Year
-99.95%All Time

Cash Data

Unlock VINC cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
523.43 K
EPS (TTM)
-19.56
P/E Ratio
-
Ent. Value
-6.27 M
Total Shares
2.24 M
Float Shares
1.54 M
Insiders
4.11%
Institutions
4.24%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every VINC catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

VINC Catalyst Timeline

Dated clinical, regulatory and corporate events for Vincerx Pharma, Inc.

Unlock the full VINC catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How VINC actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2024-12-31VIP943 Phase 1 data readout Phase 1
Unlock 2 more VINC historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Showing 3 of 3 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
VIP943 Small moleculeNCT06034275Acute Myeloid LeukemiaPhase 1 RECRUITING 36Dec 31, 2025
VIP152 Small moleculeCompletedNCT02635672NeoplasmsPhase 1 COMPLETED 110Nov 11, 2024
VIP236 Small moleculeCompletedNCT05712889NeoplasmsPhase 1 COMPLETED 29Oct 10, 2024
Unlock the VINC pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every VINC program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
OQY-3258 solid tumorsPhase 1a/1b2025-01-29intracranial ORR: 41% (n=17); PFS: 4.6 (2.0-9.8) months; historical PFS: 2.8 (1.5-3.9) monthsRead MoreVincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258Read More
Scroll for more · summaries link to the source press release
Unlock every VINC trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock VINC insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Seelenberger Alexander A.Officer (See Remarks)Buy 10,500 30,280 held$0.95 08/11/2023
Unlock the full VINC insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PROSIGHT MANAGEMENT, LP 0.4 % (-33.3 %) 1.58 M 2.21 M -11.33% ( -281.91 K)
Unlock every fund holding VINC
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in VINC
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see VINC ownership
Insider and institutional ownership, quarter by quarter.

VINC Short Interest

Shares sold short, counted twice a month.

2.94%
Short % of Float
of tradable shares sold short
966
Shares Sold Short
0.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
2.2K
Avg Daily Volume
the average used for days to cover
Unlock VINC short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock VINC option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live VINC option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock VINC options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How VINC ranks across every disease it competes in

Competitive Position is a premium feature
See how VINC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

VINC News

About Vincerx Pharma, Inc.

Ca, 94306 vincerx.com
Headquarters260 Sheridan Avenue, Suite 400, Palo Alto, CA, 94306, United States
Founded2020
BIOPHARMAWATCH ELITE PLUS
Trade the next VINC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime